Cronos Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cronos Group (CRON).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Sell

Consensus RatingUnderperform# Analysts2Avg. Consensus PT$3Upside to Avg. PT-6.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	Zuanic & Associates	Pablo Zuanic	Initiate	Overweight	—
May 15, 2024	CIBC	John Zamparo	PT Raise	Outperformer	$3→$4
Apr 8, 2024	B of A Securities	Lisa Lewandowski	PT Raise	Underperform	$2→$3
Dec 28, 2023	B of A Securities	Lisa Lewandowski	PT Raise	Underperform	$2→$2

More with Benzinga EdgeGet Access

Analyst Ratings News

This Electra Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts initiated coverage on NHP (Outperform, $20), OIG (Buy, $13), ETRA (Overweight), AHR (Strong Buy, $62).

Avi Kapoor

PRO
Zuanic & Associates Initiates Coverage On Cronos Group with Overweight Rating

Zuanic & Associates analyst Pablo Zuanic initiates coverage on Cronos Group (NASDAQ:CRON) with a Overweight rating.

Benzinga Newsdesk

Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand

Beyond Canada, this global cannabis company is focused on its international business, particularly in Germany, Australia, and the UK.

Nicolás Jose Rodriguez

Canada's Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground

Amid this slowdown, certain products capture consumer interest, even as prices stabilize and competition intensifies.

Nicolás Jose Rodriguez

Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls & Vapes As Market Eyes C$5.47B

The Canadian cannabis market is shifting towards newer product formats, with some segments outperforming cannabis flowers in sales.

Nicolás Jose Rodriguez

Aurora Cannabis Shoots For $512M Market: Marijuana Stock Analyst Initiates Coverage With Neutral

Aurora Cannabis (NASDAQ: ACB), a key player in the global medical marijuana market, stands at a strategic crossroads. Pablo Zuanic, a seasoned marijuana stock analyst from Zuanic & Associates, has initiated coverage on stock with a neutral rating.

Nicolás Jose Rodriguez

Cronos Group Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Cronos Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Electra Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Zuanic & Associates Initiates Coverage On Cronos Group with Overweight Rating

Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand

Canada's Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground

Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls & Vapes As Market Eyes C$5.47B

Aurora Cannabis Shoots For $512M Market: Marijuana Stock Analyst Initiates Coverage With Neutral

People Also Watch

People Also Watch

Cronos Group Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Cronos Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Electra Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROZuanic & Associates Initiates Coverage On Cronos Group with Overweight Rating

Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand

Canada's Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground

Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls & Vapes As Market Eyes C$5.47B

Aurora Cannabis Shoots For $512M Market: Marijuana Stock Analyst Initiates Coverage With Neutral

People Also Watch

People Also Watch

PRO
Zuanic & Associates Initiates Coverage On Cronos Group with Overweight Rating